Issue 26_February 2023
BiopharmaTrend.com, one of the top 10 biopharma online news sites, published a timely interview with Syntekabio CEO Jongson Jung about the state of artificial intelligence (AI) in drug discovery and development on Jan. 17, 2023. The full article is available on the BiopharmaTrend site.
The drug discovery market has been on an exponential growth trajectory. The expected market value is poised to reach 71 billion U.S. dollars by 2025. Korean companies are on the beat to discover new drugs, fiercely competing to capture their market share in this colossal global market. Prioritization of AI in R&D is expected to produce a fully AI-based preclinical candidate in 2023.
Syntekabio (226330:KS) is the only AI drug discovery biotech company listed on KOSDAQ among 645 artificial intelligence startups in South Korea. The company revealed its latest AI drug development platform STB CLOUD following the 2022 launch of its U.S. operations based in New York. Enabling systematic small molecule and biomarker discovery, it’s creating a buzz in the competitive drug discovery industry by cutting through vast swaths of data to speed the discovery and development of new drugs.
Since its founding in 2009, Syntekabio has built advanced AI drug discovery technology, supercomputing infrastructure and genomic big database. Using deep learning algorithms, Syntekabio developed a proprietary small molecule drug discovery technology called DeepMatcher®. It applies advanced data parsing algorithms with its own database to provide new drug candidates with high probability of success rate.
By integrating DeepMatcher®—Syntekabio’s patented AI-driven small molecule drug discovery technology—STB CLOUD has automated AI computing function within its own supercomputing hardware environment and database into a single cloud system. Delivering standardization, simplification and automation of the existing computer-aided drug discovery (CADD) process, STB CLOUD optimizes the drug discovery and development process far better in terms of time, cost, accuracy and resources to accelerate drug development feasibility and accurate prediction of drug candidates.
Syntekabio’s CEO Jongsun Jung, Ph.D., a biochemical computational scientist with extensive academic and industrial experience, has been instrumental in evolving Syntekabio’s big genome data analysis technology. According to Jung, STB CLOUD can give clinical stage pharmaceutical companies with limited drug discovery capability an ideal solution for fully automatic drug discovery. It creates their market advantage
by increasing their asset from new pipeline projects for predicted drug candidates.
From bench to bedside, AI has transformed the industry beyond recognition. AI is at the center of rational drug design. It can discover and predict effective and safe drug candidates and assist in decision making to determine the right development pathway, including personalized medicine discovery.
Syntekabio welcomes opportunities to join hands with other biotech companies and institutes interested in the initiation of new drug pipelines. The future of innovation is bright for Syntekabio.
Sabina Lee, M.A.
Senior Consultant, W Medical Strategy Group
Building on her international experience, she helps clients navigate complex issue management and cross-cultural PR and marcomms in the global environments. She has worked with a range of clients in varied sectors, including high-profile institutions, government agencies and corporations in New York, Washington D.C., Beijing, Paris and Seoul. Sabina previously served as chief media strategist for the Pulitzer Prizes and senior public affairs officer for Cornell and Columbia Universities. A graduate of Pratt Institute in New York, she attended the Middlebury Institute of International Studies in California for her M.A. in International Policy and Development.